"Cogent’s stock soars on Phase III gastrointestinal cancer data" was originally created and published by Clinical Trials ...

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...

Subcutaneous dulaglutide, semaglutide, and tirzepatide demonstrated a similar GI safety among patients with type 2 diabetes.